Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NBTXR3 |
Synonyms | |
Therapy Description |
NBTXR3 is a nanoparticle formulation of hafnium oxide, which potentially enhances radiotherapy (PMID: 31296491). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NBTXR3 | NBTXR3 is a nanoparticle formulation of hafnium oxide, which potentially enhances radiotherapy (PMID: 31296491). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04892173 | Phase III | Cetuximab NBTXR3 | NBTXR3 With or Without Cetuximab in LA-HNSCC | Recruiting | USA | SWE | ROU | ISR | HUN | HRV | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUT | 9 |
NCT03589339 | Phase I | NBTXR3 NBTXR3 + unspecified PD-1 antibody | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | Recruiting | USA | 0 |
NCT02805894 | Phase Ib/II | NBTXR3 | NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma | Terminated | USA | 0 |